Testogel ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
78Hypopituitarism1

78. Hypopituitarism


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005613-38-IE
(EUCTR)
31/05/200606/01/2006Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk?Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk? Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus, which cause diminished secretion of hypothalamic releasing hormones, thereby reducing secretion of the corresponding pituitary hormones.Trade Name: Trisequens
Trade Name: Testogel
Trade Name: Genotropin MiniQuick
Dr. Chris ThompsonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Ireland